αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd)

自分泌PD1抗体靶向间皮素嵌合抗原受体T细胞（上海细胞治疗集团有限公司）

Report date: 2024/03/28 17:42:18

Base Information

Drug NameαPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd)
Drug Alias NameaPD1-MSLN-CAR TBZDS1901BZDS-1901BZD1901
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-MesothelinAnti-PD-1
TargetsMesothelinProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Cell Therapy Group Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Cell Therapy Group Pharmaceutical Technology Co LtdShanghai Cell Therapy Group Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal Neoplasms
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsMesothelioma

Other Information

ATC CodeN/A
Related LinksN/A